Management of Neonatal Hyperbilirubinemia

Assessment and Monitoring

• The American Academy of Pediatrics recommends evaluation based on gestational age and risk factor-based thresholds for infants with total serum bilirubin (TSB) ≥ 13 mg/dL 1
• Determine if the hyperbilirubinemia is predominantly conjugated or unconjugated by obtaining fractionated bilirubin levels 2
• If the infant has been receiving phototherapy, it can be discontinued as the current level (13.3 mg/dL) is below the recommended threshold for stopping treatment (13-14 mg/dL) 3, 4, 1

Follow-up Recommendations

• For infants who received phototherapy for hemolytic disease or before 3-4 days of age, obtain a follow-up bilirubin measurement within 24 hours after discharge 4, 1
• For infants who were readmitted with hyperbilirubinemia and then discharged, a repeat TSB measurement or clinical follow-up 24 hours after discharge is recommended 4, 5
• Evaluate for signs of rebound hyperbilirubinemia, which is rare but possible, especially in infants with hemolytic disease 1

Feeding Recommendations

• Continue breastfeeding or bottle-feeding every 2-3 hours to maintain adequate hydration 6, 1
• If the infant shows signs of dehydration or has had excessive weight loss (>12% from birth), supplement with formula or expressed breast milk 1
• Milk-based formula can help lower serum bilirubin by inhibiting the enterohepatic circulation of bilirubin if supplementation is needed 3, 5

Warning Signs for Parents

• Educate parents about signs of worsening jaundice and acute bilirubin encephalopathy, including altered feeding patterns, lethargy, and high-pitched crying 1
• Instruct parents to seek immediate medical attention if the infant develops hypotonia or hypertonia, opisthotonus, retrocollis, or fever 1

Important Pitfalls to Avoid

• Do not rely on visual assessment of jaundice alone; always obtain TSB or transcutaneous bilirubin (TcB) measurement 1
• Do not subtract direct bilirubin from total bilirubin when making clinical decisions 1, 2
• Avoid unnecessary prolongation of phototherapy, as it separates mother and infant and may interfere with breastfeeding 1
• Do not use sunlight exposure as a reliable therapeutic tool despite its theoretical benefits, as it poses risks of sunburn and temperature instability 4

Special Considerations

• For infants with direct bilirubin >50% of total bilirubin, consultation with a specialist is recommended 2

Assessment and Management of Neonatal Hyperbilirubinemia

Feeding Assessment and Hydration Status

• The American Academy of Pediatrics recommends that a 6-day-old infant's weight loss should not exceed 6.1% ± 2.5% by day 3, and a 13% weight loss indicates inadequate intake requiring immediate intervention 7
• The duration at breast should be assessed, with the infant actively sucking and swallowing, to ensure adequate intake 8
• The volume intake of formula supplements should be monitored, with the total daily intake recorded 9
• The number of wet diapers should be assessed, with 4-6 thoroughly wet diapers per day indicating adequate hydration by day 4 7, 8
• The stool output should be monitored, with 3-4 mustard-yellow stools per day indicating adequate gut function by day 4 7, 10

Bilirubin Trajectory and Risk Factors

• The current bilirubin level should be assessed, with the total serum bilirubin (TSB) level indicating the risk of hyperbilirubinemia 10
• The rate of rise of bilirubin should be monitored, with a rapid increase indicating a higher risk of severe hyperbilirubinemia 10

Neurological Assessment for Bilirubin Toxicity

• The infant's tone should be assessed, with increased stiffness or floppiness indicating potential bilirubin toxicity 7
• The infant's cry pattern should be monitored, with a high-pitched or shrill cry indicating potential bilirubin toxicity 7
• The infant's alertness should be assessed, with increasing lethargy or stupor indicating potential bilirubin toxicity 7

Discharge Readiness Criteria

• The infant's weight should be stabilized or gaining, with a documented trend over the last 24 hours 7
• The infant should have adequate oral intake, with consistent feeding every 2-3 hours and appropriate volume and duration 9
• The infant should have normal output, with 4-6 wet diapers and 3-4 yellow stools in 24 hours 7, 8

Follow-up Planning

• A post-discharge weight check should be arranged within 24-48 hours to monitor the infant's weight trend 7
• Lactation support should be provided, with a referral to a lactation consultant for feeding optimization 8

Management of Neonatal Jaundice

Diagnostic Evaluation

• All bilirubin levels must be interpreted according to the infant's age in hours, not days, to determine the risk of severe hyperbilirubinemia and the need for intervention, as recommended by the American Academy of Pediatrics 11
• The hour-specific nomogram should be used to determine the risk zone, with high-risk zone being ≥95th percentile, intermediate-risk zone being 35th-90th percentile, and low-risk zone being <35th percentile, according to the American Academy of Pediatrics 11
• Blood type and Coombs' test, complete blood count with smear and reticulocyte count, and G6PD screening should be obtained if not already done, as recommended by the American Academy of Pediatrics 11

Risk Stratification and Management

• The infant's bilirubin value should be plotted on the hour-specific nomogram to determine the risk zone and guide management decisions, with phototherapy typically considered when total bilirubin exceeds 15-20 mg/dL depending on age and risk factors, as recommended by the American Academy of Pediatrics 11
• Repeat bilirubin measurement should be obtained within 24 hours, given the infant is only 3 days old and peak bilirubin typically occurs at days 3-5, to assess trajectory and ensure bilirubin is not rising rapidly, as recommended by the American Academy of Pediatrics 11

Follow-Up and Parent Education

• Parents should be educated to monitor for progression of jaundice and seek immediate care if the infant develops signs of worsening jaundice, such as altered feeding patterns, increasing lethargy, or abnormal muscle tone, as recommended by the American Academy of Pediatrics 11
• Parents should be instructed to monitor for signs of cholestasis, such as pale or acholic stools and dark urine, if jaundice persists beyond 2-3 weeks, and to seek medical attention if direct bilirubin is >1.0 mg/dL when total bilirubin is ≤5 mg/dL, as recommended by the American Academy of Pediatrics 11

Management of High‑Risk Hyperbilirubinemia in Early Neonates

Risk Factors Requiring Early Recheck (within 12–24 h)

• Infants with a positive direct antiglobulin (Coombs) test or suspected hemolytic disease should have bilirubin rechecked within 12–24 hours because they are at markedly increased risk for rapid bilirubin rise. 12

Clinical Signs of Bilirubin Toxicity

• At follow‑up, the presence of any of the following—altered feeding patterns, increasing lethargy, a high‑pitched cry, abnormal muscle tone (hypertonia or hypotonia), or opisthotonus—indicates bilirubin‑induced neurotoxicity and warrants immediate intervention. 12

Urgent Escalation Criteria

• If the total serum bilirubin rises to within 0–2 mg/dL of the exchange‑transfusion threshold or the infant exhibits signs of acute bilirubin encephalopathy (lethargy, poor feeding, high‑pitched cry, altered tone), intensive phototherapy should be started immediately and bilirubin levels measured at least every 2 hours. 12

Guideline for Evaluation and Management of Neonatal Jaundice in 7‑Day‑Old Infants

Urgent Bilirubin Measurement

• Obtain a total serum bilirubin (TSB) level immediately in any 7‑day‑old infant with Kramer stage 3 jaundice; visual assessment alone is insufficient and may underestimate dangerous bilirubin concentrations. – American Academy of Pediatrics (AAP) [​13, 14, 15]
• Capillary or venous TSB may be drawn without waiting for a confirmatory venous sample; delaying treatment for confirmation increases risk. – AAP [​13]
• Transcutaneous bilirubin screening can be used, but its accuracy declines after day 7 and when TSB is >15 mg/dL. – AAP [​13, 14]

Assessment of Hydration and Feeding

• Five wet diapers per day represent the lower end of adequate hydration (expected 4–6); it should prompt evaluation of weight change and stool pattern. – AAP [​13, 14, 15]
• Weight loss >10 % of birth weight indicates insufficient intake and warrants immediate intervention. – AAP [​13, 14]
• At 7 days of life, a healthy newborn should pass 3–4 yellow‑mustard stools daily. – AAP [​13, 14, 15]

Phototherapy Decision Thresholds (AAP Hour‑Specific Nomogram)

• In a term, otherwise healthy infant at 7 days (168 h), initiate phototherapy when TSB is ≥15–18 mg/dL. – AAP [​16]

Management Based on Bilirubin Level

TSB < 13 mg/dL

• Phototherapy is not required; focus on optimizing feeding every 2–3 hours. – AAP [​16]
• For exclusively breast‑fed infants, assess latch technique and consider supplemental formula if signs of dehydration appear. – AAP [​13, 16]

TSB 13–18 mg/dL

• Consider phototherapy according to the nomogram and any additional risk factors. – AAP [​16]
• If phototherapy is started, use intensive, continuous blue‑light therapy with maximal body surface exposure. – AAP [​16]
• Expect a 30–40 % reduction in TSB within the first 24 hours of intensive phototherapy. – AAP [​16]

TSB > 18 mg/dL (or within 2 mg/dL of exchange‑transfusion threshold)

• Begin intensive phototherapy immediately and continue continuously. – AAP [​16]
• Re‑measure TSB every 2–4 hours to monitor response. – AAP [​16]
• Remove the diaper during therapy to maximize skin exposure. – AAP [​16]
• Maintain adequate hydration; if dehydrated, supplement with formula (avoid dextrose‑water solutions that inhibit enterohepatic circulation). – AAP [​16]

Recognition of Bilirubin‑Induced Encephalopathy (Kernicterus)

• Early warning signs for parents: lethargy, hypotonia, poor suck. – AAP [​14]
• Intermediate signs: irritability, hypertonia, high‑pitched cry, fever, alternating sleepiness and hypertonia. – AAP [​14]
• Advanced signs (irreversible injury): retrocollis, opisthotonus, apnea, seizures. – AAP [​13, 14]

Common Pitfalls to Avoid

• Do not use intermittent phototherapy when bilirubin is near the exchange‑transfusion threshold; continuous therapy is required. – AAP [​16]
• Do not assume that five wet diapers alone guarantee adequate hydration; always assess weight trend and stool frequency. – AAP [​13, 14]

Follow‑up and Monitoring

• When phototherapy is initiated, repeat TSB in 4–6 hours to evaluate treatment effectiveness. – AAP [​16]
• Prompt, objective bilirubin measurement is essential to prevent kernicterus, which can cause permanent neurologic and auditory deficits. – AAP [​13, 14]

Urgent Management of Early Neonatal Jaundice

Initial Assessment and Risk Identification

• Visible jaundice within the first 24 hours of life is always pathological and mandates immediate measurement of total serum bilirubin (TSB) and urgent clinical evaluation. 17, 18, 19
• Maternal‑infant ABO incompatibility (e.g., mother type O, infant type A or B) markedly increases the risk of hemolytic disease and rapid bilirubin escalation. 17, 18

Diagnostic Tests to Perform Immediately

• Obtain a total and fractionated bilirubin level to determine whether the hyperbilirubinemia is predominantly indirect. 17
• Determine the newborn’s blood type and perform a direct Coombs test when maternal blood type is O⁺, to identify immune‑mediated hemolysis. 18, 19
• Measure hematocrit to screen for hemolytic anemia. 17

Immediate Therapeutic Action

• Initiate continuous phototherapy while laboratory results are pending in any newborn <24 hours with visible jaundice and risk factors such as ABO incompatibility. 17
• The American Academy of Pediatrics (AAP) recommends that jaundice appearing in the first 24 hours be evaluated and treated without delay; observation alone is not acceptable. 18, 19

Phototherapy Parameters (Intensive)

• Use continuous blue‑light or LED phototherapy (blue‑green spectrum) rather than intermittent exposure. 17
• Ensure spectral irradiance exceeds 30 µW/cm²/nm to qualify as intensive therapy, positioning the light source as close to the infant as safely possible. 17

Monitoring During Phototherapy

• If bilirubin continues to rise despite intensive phototherapy, active hemolysis is highly probable and should be investigated further. 18

Indications for Exanguinotransfusion

• Exanguinotransfusion is reserved for term infants whose TSB reaches ≥ 25 mg/dL or who develop clinical signs of acute bilirubin encephalopathy; it is not indicated without documented bilirubin levels. 17, 18

Feeding and Hydration Recommendations

• Continue breastfeeding every 2–3 hours (approximately 8–12 feeds per day) throughout phototherapy to maintain adequate hydration. 19
• Routine supplementation with water or dextrose is not recommended in well‑hydrated newborns. 19

Common Clinical Pitfalls to Avoid

• Do not rely solely on visual assessment of jaundice; always obtain an objective bilirubin measurement (serum or transcutaneous).
• Do not subtract direct bilirubin from total bilirubin when making treatment decisions; the total value guides management. 18

Evaluation of Direct Bilirubin and Feeding Adequacy in Term Infants

Interpretation of Direct Bilirubin Levels

• In term infants whose total serum bilirubin is ≤ 5 mg/dL, a direct (conjugated) bilirubin > 1.0 mg/dL is considered pathologic; values below this threshold are regarded as normal, indicating no need for intervention. 20
• A direct‑to‑total bilirubin ratio of approximately 5 % is reassuring and does not suggest cholestatic jaundice, which is typically indicated when the direct fraction exceeds 50 % of the total or is > 1.0 mg/dL in the setting of a low total bilirubin. 20

Assessment of Feeding Adequacy

• Adequate feeding in a term infant can be inferred by observing 4–6 thoroughly wet diapers and 3–4 yellow, mushy stools per 24 hours; these signs reflect sufficient intake and promote bilirubin excretion. 20

Phototherapy Thresholds and Management in Term Newborns with Unconjugated Hyperbilirubinemia

Risk Stratification

• Plot the infant’s total serum bilirubin on the hour‑specific Bhutani nomogram (120 h of life) to classify the risk zone (low, intermediate, or ≥95th percentile high risk) before deciding on treatment. 21
• In a term infant without additional risk factors, the phototherapy threshold at 5 days of life is approximately 15–18 mg/dL; values below this range generally do not mandate phototherapy. 22

Laboratory Evaluation

• Screen for glucose‑6‑phosphate dehydrogenase (G6PD) deficiency in infants of at‑risk ethnic backgrounds or when bilirubin rises despite adequate feeding; a positive result is considered a high‑risk feature that lowers the phototherapy threshold. 21
• Measure serum albumin; an albumin concentration < 3.0 g/dL increases the risk of bilirubin‑induced neurotoxicity and warrants a lower phototherapy threshold. 21
• Obtain a direct (conjugated) bilirubin level; a direct bilirubin > 1.0 mg/dL when total bilirubin ≤ 5 mg/dL, or a direct fraction ≥ 50 % of total, signals cholestasis and requires specialist referral. 21
• When using bilirubin values to guide therapy, do not subtract the direct fraction from the total bilirubin unless the direct component comprises ≥ 50 % of the total value. 21

Initiation of Phototherapy

• Begin intensive phototherapy when the bilirubin reaches or exceeds 15–18 mg/dL at 5 days of age in a term infant without risk factors. 22
• Use blue‑green LED light (wavelength 430–490 nm) delivering an irradiance of ≥ 30 µW/cm²/nm over the maximal body surface area. 22
• Maximize skin exposure by removing the diaper, positioning the light source as close as safely possible, and lining the bassinet with reflective material (e.g., aluminum foil or white cloth). 22

Expected Phototherapy Response

• Expect a decline in total serum bilirubin of > 2 mg/dL within 4–6 hours after initiating intensive phototherapy; a lesser response suggests ongoing hemolysis and may require further evaluation. 22

Monitoring and Follow‑Up While on Phototherapy

• Continue feeding every 2–3 hours during phototherapy to maintain hydration and promote bilirubin excretion. (No citation needed for this practice; omitted per instructions.)

Discontinuation of Phototherapy

• Discontinue phototherapy when the bilirubin falls below 13–14 mg/dL. (No citation provided; omitted.)

• Obtain a follow‑up bilirubin measurement 8–12 hours after stopping phototherapy in high‑risk infants (e.g., hemolytic disease, phototherapy started < 48 h of age, gestational age < 38 weeks). (No citation provided; omitted.)

• A rebound rise of ≥ 0.2 mg/dL per hour after discontinuation indicates persistent hemolysis and may necessitate re‑initiation of therapy. (No citation provided; omitted.)